Acurx Pharmaceuticals LLC (ACXP) - Net Assets
Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) has net assets worth $7.01 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.54 Billion) and total liabilities ($2.53 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ACXP goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.01 Billion |
| % of Total Assets | 73.51% |
| Annual Growth Rate | 36.34% |
| 5-Year Change | -57.55% |
| 10-Year Change | N/A |
| Growth Volatility | 297.79 |
Acurx Pharmaceuticals LLC - Net Assets Trend (2019–2025)
This chart illustrates how Acurx Pharmaceuticals LLC's net assets have evolved over time, based on quarterly financial data. See ACXP days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Acurx Pharmaceuticals LLC (2019–2025)
The table below shows the annual net assets of Acurx Pharmaceuticals LLC from 2019 to 2025. For live valuation and market cap data, see Acurx Pharmaceuticals LLC market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.27 Million | +756.51% |
| 2024-12-31 | $615.12K | -86.82% |
| 2023-12-31 | $4.67 Million | -36.20% |
| 2022-12-31 | $7.32 Million | -41.06% |
| 2021-12-31 | $12.41 Million | +359.37% |
| 2020-12-31 | $2.70 Million | +229.52% |
| 2019-12-31 | $819.85K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Acurx Pharmaceuticals LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6608792000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.35K | 0.04% |
| Other Components | $80.55 Million | 1528.96% |
| Total Equity | $5.27 Million | 100.00% |
Acurx Pharmaceuticals LLC Competitors by Market Cap
The table below lists competitors of Acurx Pharmaceuticals LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Porvair plc
LSE:PRV
|
$4.40 Million |
|
Oakajee Corporation Ltd
AU:OKJ
|
$4.40 Million |
|
Pomvom
TA:PMVM
|
$4.40 Million |
|
Infinity Lithium Corporation Ltd
AU:INF
|
$4.41 Million |
|
Pelangi Indah Canindo Tbk
JK:PICO
|
$4.40 Million |
|
CN Asia Corporation Bhd
KLSE:7986
|
$4.39 Million |
|
Parx Plastics NV
PA:MLPRX
|
$4.39 Million |
|
Amatheon Agri Holding NV
PA:MLAAH
|
$4.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acurx Pharmaceuticals LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 615,121 to 5,268,592, a change of 4,653,471 (756.5%).
- Net loss of 7,966,538 reduced equity.
- Share repurchases of 3,808,439,000 reduced equity.
- New share issuances of 6,797,112 increased equity.
- Other factors increased equity by 3,814,261,897.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.97 Million | -151.21% |
| Share Repurchases | $3.81 Billion | -72285.71% |
| Share Issuances | $6.80 Million | +129.01% |
| Other Changes | $3.81 Billion | +72396.23% |
| Total Change | $- | 756.51% |
Book Value vs Market Value Analysis
This analysis compares Acurx Pharmaceuticals LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.44x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.90x to 0.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.72 | $1.54 | x |
| 2020-12-31 | $5.45 | $1.54 | x |
| 2021-12-31 | $24.30 | $1.54 | x |
| 2022-12-31 | $13.53 | $1.54 | x |
| 2023-12-31 | $7.37 | $1.54 | x |
| 2024-12-31 | $0.72 | $1.54 | x |
| 2025-12-31 | $3.51 | $1.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acurx Pharmaceuticals LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -151.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.46x
- Recent ROE (-151.21%) is above the historical average (-559.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -723.45% | 0.00% | 0.00x | 3.09x | $-6.01 Million |
| 2020 | -170.27% | 0.00% | 0.00x | 1.19x | $-4.87 Million |
| 2021 | -102.18% | 0.00% | 0.00x | 1.07x | $-13.92 Million |
| 2022 | -165.31% | 0.00% | 0.00x | 1.28x | $-12.82 Million |
| 2023 | -312.38% | 0.00% | 0.00x | 1.65x | $-15.04 Million |
| 2024 | -2292.74% | 0.00% | 0.00x | 6.27x | $-14.16 Million |
| 2025 | -151.21% | 0.00% | 0.00x | 1.46x | $-8.49 Million |
Industry Comparison
This section compares Acurx Pharmaceuticals LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acurx Pharmaceuticals LLC (ACXP) | $7.01 Billion | -723.45% | 0.36x | $4.40 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more